Abstract
The transforming growth factor-β (TGF-β) superfamily includes TGF-β s, activin, myostatin and bone morphogenetic proteins. Misregulation of the activity of TGF-β family members is involved in pathogenesis of cancer, muscular dystrophy, obesity and bone and tooth remodeling. Natural inhibitors for the TGF-β superfamily regulate fine-tuning of activity of TGF-β family in vivo. In addition to natural inhibitors for the TGF-β family, soluble forms of receptors for the TGF-β family, blocking monoclonal antibodies and small chemical TGF-β inhibitors have been developed. In this review, we summarize recent advances in our understanding of inhibitors for the TGF-β superfamily and their medical applications.
| Original language | English |
|---|---|
| Pages (from-to) | 1255-1261 |
| Number of pages | 7 |
| Journal | Mini-Reviews in Medicinal Chemistry |
| Volume | 6 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 11-2006 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Pharmacology
- Drug Discovery
- Cancer Research
Fingerprint
Dive into the research topics of 'Inhibitors of the TGF-β superfamily and their clinical applications'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver